AbbVie ABBV Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.64B-13.8% | $4.23B-1.8% | $2.42B-52.9% | $3.79B-29.1% | $4.23B-29.6% | ||
| $989M+1.6% | $955M+4.8% | $962M+10.3% | $934M+13.8% | $973M+24.4% | ||
| —— | —— | —— | -$1.34B+49.5% | -$1.09B+63.9% | ||
| —— | —— | $1.27B— | —— | —— | ||
| $265M-33.6% | $236M-26.0% | $339M— | $403M— | $399M— | ||
| —— | —— | —— | —— | -$881M-119% | ||
| $21.22B+29.4% | $19.03B+1.2% | $20.86B+26.3% | $19.28B+3.5% | $16.4B-27.7% | ||
| $1.24B+22.4% | $1.21B+24.6% | $1.18B+32.4% | $1.04B+21.7% | $1.02B+27.8% | ||
| —— | —— | —— | —— | —— | ||
| -$6.48B+45.8% | -$6.64B+68.1% | -$7.05B+64.3% | -$12.05B-1.6% | -$11.97B-7.8% | ||
| $11.82B+5.7% | $11.66B+5.7% | $11.5B+5.5% | $11.34B+5.2% | $11.18B+5.0% | ||
| $1.51B+12.1% | $980M-42.6% | $1.34B-1.3% | $1.35B+0.6% | $1.35B+0.3% | ||
| —— | —— | —— | —— | —— | ||
| -$10.55B— | -$12.72B— | -$15.42B— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $4.22B+133% | -$295M+96.0% | -$1.63B— | -$6.66B— | -$12.89B— | ||
| —— | $3B+6.8% | $2.95B+8.4% | $2.91B+10.1% | $2.86B+11.9% | ||
| —— | —— | -$902M-976% | -$269M+9.7% | -$209M— | ||
| $42M— | $3M— | —— | —— | —— | ||
| $3.04B+41.1% | $2.87B+43.6% | $2.72B+41.9% | $2.53B+46.1% | $2.15B+72.7% | ||
| $7.33B-2.9% | $7.44B-1.9% | $7.55B-0.3% | $7.55B-1.6% | $7.55B-4.1% | ||
| $7.36B+59.1% | $6.5B+72.2% | $5.37B+3.5% | $5.95B+54.9% | $4.63B+18.2% | ||
| $769M+0.9% | $762M-0.3% | $765M+2.7% | $764M+1.9% | $762M+0.8% | ||
| —— | —— | -$3.21B— | -$2.8B— | -$3.26B— | ||
| —— | —— | —— | —— | —— | ||
| $42M— | $3M— | —— | —— | —— | ||
| $110M+147% | $29M+115% | -$169M— | -$249M— | -$233M— | ||
| $5.17B+63.2% | $5.24B+73.2% | $5.87B+229% | $3.27B+87.3% | $3.17B+199% | ||
| $4.8B— | $2.8B— | —— | —— | —— | ||
| —— | —— | —— | —— | $100M— | ||
| —— | —— | —— | —— | $1.59B— | ||
| $3.77B-69.9% | $6.8B-29.3% | $12.55B+122% | $12.95B+147% | $12.54B+332% | ||
| —— | —— | —— | —— | —— | ||
| $19.98B+29.9% | $17.82B-0.1% | $19.68B+26.0% | $18.24B+2.6% | $15.39B-29.7% | ||
| $19.98B+29.9% | $17.82B-0.1% | $19.68B+26.0% | $18.24B+2.6% | $15.39B-29.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does AbbVie generate?
- AbbVie (ABBV) generated $21.2B in operating cash flow over the trailing twelve months.
- What is AbbVie's free cash flow?
- After $1.2B of capital expenditures, AbbVie's free cash flow was $20.0B over the trailing twelve months, up 29.9% year over year.
- Where does AbbVie's cash flow data come from?
- Every line is extracted from AbbVie's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
